DNMT3A mutations emerged as potential biomarkers for enhanced immunotherapy benefit in non-small cell lung cancer.

In vivo CAR T cell generation is a pioneering immunotherapy approach that reprograms the immune system to fight cancer and ...

两项重磅研究 (Ely et al.和Apavaloaei et al.)颠覆性揭示：在众多癌症的免疫肽组 (immunopeptidome)中，源自非编码区 (untranslated regions)的未突变非经典抗原 (non-canonical antigens)竟占据主导地位。这一发现直接挑战了传统"突变中心论"免疫疗法，犹如在肿瘤抗原宇宙中发现新大陆。研究者们兴奋地指出，隐蔽抗原 ...

The findings also suggest that high levels of sClever-1 are associated with resistance to anti-PD-1 checkpoint inhibitors, identifying sClever-1 as a potential biomarker to guide immunotherapy ...

Welcome to the second installment of "Cancer and the Gut Microbiome: A Miniseries". Here, we focus on how the microbiome ...

Dubai, United Arab Emirates; June, 2025 - Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic ...

The report indicates >25 clinical trials, with the highest phase being Phase II/III as of June 2025. The US and China lead with >20 trials. Gamma Delta T Cell therapy, promising in treating blood ...

The immune system is central to identifying and eliminating foreign pathogens that enter the body. The innate and adaptive immune responses work together t | Immunology ...

Birmingham has a very strong history of immunology research going back 30 years, and with one of the greatest concentrations of scientists and doctors in the world is well positioned to make a ...

(12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) <li /> EO ...

AI precision-medicine company Sonrai Analytics and German biotech Plectonic Biotech have entered a partnership to accelerate ...

Making CAR-T cells, though, is an art, with so many possible variables that it can be hard to hit on one that works. And it ...